About Sestrin-3
Sestrin-3 (SESN3) is a protein
from Homo sapiens identified by UniProt accession
P58005, 492 residues long.
MolForge cross-references it against 0 known binders and
148 disease associations.
Target properties
| Protein name | Sestrin-3 |
|---|
| UniProt accession | P58005 |
|---|
| Gene | SESN3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 492 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (148)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.40
- eosinophil count · score 0.37
- monocyte count · score 0.32
- erythrocyte count · score 0.31
- Red cell distribution width · score 0.31
- leukocyte count · score 0.30
- protein measurement · score 0.29
- mean corpuscular volume · score 0.29
- sex hormone-binding globulin measurement · score 0.29
- myeloid white cell count · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P58005-F1 | alphafold | PREDICTED | 81.47 | — |
Amino-acid sequence (492 residues)
MNRGGGSPSA AANYLLCTNC RKVLRKDKRI RVSQPLTRGP SAFIPEKEVV QANTVDERTN FLVEEYSTSG RLDNITQVMS LHTQYLESFL RSQFYMLRMD GPLPLPYRHY IAIMAAARHQ CSYLINMHVD EFLKTGGIAE WLNGLEYVPQ RLKNLNEINK LLAHRPWLIT KEHIQKLVKT GENNWSLPEL VHAVVLLAHY HALASFVFGS GINPERDPEI SNGFRLISVN NFCVCDLAND NNIENASLSG SNFGIVDSLS ELEALMERMK RLQEEREDEE ASQEEMSTRF EKEKKESLFV VSGDTFHSFP HSDFEDDMII TSDVSRYIED PGFGYEDFAR RGEEHLPTFR AQDYTWENHG FSLVNRLYSD IGHLLDEKFR MVYNLTYNTM ATHEDVDTTM LRRALFNYVH CMFGIRYDDY DYGEVNQLLE RSLKVYIKTV TCYPERTTKR MYDSYWRQFK HSEKVHVNLL LMEARMQAEL LYALRAITRH LT
Explore Sestrin-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets